BioAdvance
BioAdvance is an evergreen venture fund that invests in early-stage life-science companies, with a geographic focus on the Mid-Atlantic region. The firm describes a long-term investment perspective and reports that its portfolio companies have attracted over $4.2 billion of external capital.
BioAdvance
Philadelphia, Pennsylvania, United States, North America
Services
Early-stage equity investment
Provides capital to early-stage life-science companies.
Evergreen, long-term capital
Operates as an evergreen fund offering a long-term investment perspective.
Early-stage equity investment
Provides capital to early-stage life-science companies.
Evergreen, long-term capital
Operates as an evergreen fund offering a long-term investment perspective.
Portfolio
Developed an RNAi molecule to treat macular degeneration. Merged into Opko Health, Inc. in 2007.
#RNA therapeutics / ophthalmology
Holds a platform exploiting protein-conformation dynamics to discover next-generation GPCR drugs aimed at reducing on-target side effects.
#GPCR drug discovery / therapeutics platform
Developed therapeutics and vaccines (CDX-110) against proprietary cancer targets; acquired by Celldex Therapeutics in 2005.
#Cancer therapeutics / vaccines
Company developing a novel approach to CDK4 inhibition intended to limit development of resistance seen with current therapies. Women-founded and run.
#Oncology / metastatic breast cancer therapeutics
Developed sensor-based technologies and a platform to improve medication adherence and care coordination in respiratory care.
#Digital health / respiratory care devices and platforms
Provides an allogeneic human TSC platform as a starting cell source for cell and gene therapy.
#Cell & gene therapy / allogeneic Trophoblast Stem Cell (TSC) platform
Developed an RNAi molecule to treat macular degeneration. Merged into Opko Health, Inc. in 2007.
#RNA therapeutics / ophthalmology
Holds a platform exploiting protein-conformation dynamics to discover next-generation GPCR drugs aimed at reducing on-target side effects.
#GPCR drug discovery / therapeutics platform
Developed therapeutics and vaccines (CDX-110) against proprietary cancer targets; acquired by Celldex Therapeutics in 2005.
#Cancer therapeutics / vaccines
Company developing a novel approach to CDK4 inhibition intended to limit development of resistance seen with current therapies. Women-founded and run.
#Oncology / metastatic breast cancer therapeutics
Developed sensor-based technologies and a platform to improve medication adherence and care coordination in respiratory care.
#Digital health / respiratory care devices and platforms
Provides an allogeneic human TSC platform as a starting cell source for cell and gene therapy.
#Cell & gene therapy / allogeneic Trophoblast Stem Cell (TSC) platform